CYP2C8 and antimalaria drug efficacy.
CYP2C8 and antimalaria drug efficacy.
复制标题
DOI：
10.2217/14622416.8.2.187
复制
发表时间：
2007-03
期刊：
影响因子：
2.1
通讯作者：
Gil Berglund E
中科院分区：
文献类型：
--
作者：
Gil JP;Gil Berglund E
Malaria is a major infectious disease. In the last 10 years it has killed more than 20 million people, mainly small children in Africa. The highly efficacious artemisinine combination therapy is being launched globally, constituting the main hope for fighting the disease. Amodiaquine is a main partner in these combinations. Amodiaquine is almost entirely metabolized by the polymorphic cytochrome P450 (CYP) isoform 2C8 to the pharmacologically active desethylamodiaquine. The question remains whether the efficacy of amodiaquine is affected by the gene polymorphism. Genotype-inferred low metabolizers are found in 1–4% of African populations, which corresponds to millions of expected exposures to the drug. In vivo pharmacokinetic data on amodiaquine is limited. By combining it with published in vitro pharmacodynamic and drug metabolism information, we review and predict the possible relevance, or lack of, of CYP2C8 polymorphisms in the present and future efficacy of amodiaquine. Chloroquine and dapsone, both substrates of CYP2C8, are also discussed in the same context.
登录
查看更多内容
影响因子：
6.8
作者：
Cavaco, I;Piedade, R;Ribeiro, V
通讯作者：
Ribeiro, V
影响因子：
168.9
作者：
Alloueche, A;Bailey, W;Winstanley, PA
通讯作者：
Winstanley, PA
DOI：
10.1097/00008571-200110000-00006
发表时间：
2001-10-01
期刊：
PHARMACOGENETICS
影响因子：
--
作者：
Dai, D;Zeldin, DC;Goldstein, JA
通讯作者：
Goldstein, JA
DOI：
10.1590/s0074-02762006000300022
发表时间：
2006-05-01
期刊：
Memórias do Instituto Oswaldo Cruz
影响因子：
--
作者：
Echeverry, Diego F;Murillo, Claribel;Osorio, Lyda
通讯作者：
Osorio, Lyda
影响因子：
6.1
作者：
CHURCHILL, FC;PATCHEN, LC;DICKINSON, CM
通讯作者：
DICKINSON, CM